Pharma Focus Europe

GENESIS Pharma Secures Exclusive Distribution Agreement with Regeneron Pharmaceuticals to Commercialize Cemiplimab in Greece, Cyprus, and Malta

Saturday, March 02, 2024

GENESIS Pharma, a regional biopharmaceutical company specializing in bringing innovative medicines for severe and rare diseases to Central and Eastern Europe, has announced an exclusive distribution agreement for the cancer drug cemiplimab in Greece, Cyprus, and Malta with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron, a leading biotechnology company focused on developing transformative medicines for serious diseases.

Cemiplimab, a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, was developed using Regeneron's VelocImmune® technology. In the European Union, cemiplimab is indicated for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), and recurrent or metastatic cervical cancer.

Both companies aim to smoothly transition all relevant commercialization activities by the second quarter of 2024.

Mr. Constantinos Evripides, Managing Director of GENESIS Pharma, remarked: “For over 20 years, our company has been dedicated to ensuring patient access to innovative therapies for serious diseases in various European markets, collaborating with leading global biopharmaceutical companies. We are honored to establish this new agreement with Regeneron, a pioneering company committed to cutting-edge science, further solidifying our expertise and focus on medicines for difficult-to-treat cancers.”

 

Source: genesispharmagroup.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva